Pacira BioSciences, Inc.
US ˙ NasdaqGS ˙ US6951271005

Introduction

This page provides a comprehensive analysis of the known insider trading history of Shawn Cross. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Shawn Cross has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CYTH / Cyclo Therapeutics, Inc. Director 136,346
US:PCRX / Pacira BioSciences, Inc. Chief Financial Officer 75,000
US:AMTI / Applied Molecular Transport Inc. CEO & Chair of the Board, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Shawn Cross. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PCRX / Pacira BioSciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PCRX / Pacira BioSciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Sales PCRX / Pacira BioSciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PCRX / Pacira BioSciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Shawn Cross as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-03 2025-02-27 4 CYTH Cyclo Therapeutics, Inc.
Common Stock
A - Award 28,597 136,346 26.54
2024-11-18 2024-11-15 4 CYTH Cyclo Therapeutics, Inc.
Common Stock
A - Award 17,228 107,749 19.03
2024-11-05 2024-11-01 4 PCRX Pacira BioSciences, Inc.
Common Stock
A - Award 75,000 75,000
2024-08-20 2024-08-16 4 CYTH Cyclo Therapeutics, Inc.
Common Stock
A - Award 9,028 90,521 11.08
2024-06-05 2024-06-03 4 CYTH Cyclo Therapeutics, Inc.
Common Stock
A - Award 8,887 81,493 12.24
2023-12-28 2023-12-27 4 AMTI Applied Molecular Transport Inc.
Common Stock
D - Sale to Issuer -545,499 0 -100.00
2023-12-28 3 CYTH Cyclo Therapeutics, Inc.
Common Stock
0
2023-12-28 2023-12-27 4 CYTH Cyclo Therapeutics, Inc.
Common Stock
A - Award 72,606 72,606
2023-11-24 2023-11-22 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -110,802 545,499 -16.88 0.16 -18,116 89,189
2023-11-16 2023-11-15 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -90,447 656,301 -12.11 0.16 -14,526 105,402
2023-10-04 2023-09-05 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -1,253 746,748 -0.17 0.21 -260 154,950
2023-10-04 2023-06-02 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -477 748,001 -0.06 0.24 -115 179,670
2023-10-04 2023-06-02 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -536 748,478 -0.07 0.24 -129 179,934
2023-10-04 2023-06-02 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -3,293 749,014 -0.44 0.24 -794 180,662
2023-10-02 2023-09-29 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -193,960 752,307 -20.50 0.16 -30,743 119,241
2023-10-02 2023-09-28 4 AMTI Applied Molecular Transport Inc.
Common Stock
A - Award 886,111 946,267 1,473.02
2023-03-03 2023-03-01 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -934 60,156 -1.53 0.50 -467 30,078
2022-12-06 2022-12-02 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -3,893 61,090 -5.99 1.05 -4,088 64,151
2022-09-06 2022-09-01 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -416 64,983 -0.64 1.42 -591 92,269
2022-09-06 2022-09-01 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -468 65,399 -0.71 1.42 -665 92,886
2022-06-03 2022-06-02 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -2,166 65,867 -3.18 3.04 -6,590 200,400
2022-06-03 2022-06-01 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale -1,767 67,983 -2.53 2.97 -5,244 201,767
2022-05-18 2022-05-16 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy)
A - Award 84,000 84,000
2022-05-18 2022-05-16 4 AMTI Applied Molecular Transport Inc.
Common Stock
A - Award 18,000 69,750 34.78
2022-02-16 2022-02-15 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy)
A - Award 94,500 94,500
2022-02-16 2022-02-15 4 AMTI Applied Molecular Transport Inc.
Common Stock
A - Award 20,250 51,750 64.29
2022-01-06 2021-12-24 4 AMTI Applied Molecular Transport Inc.
Common Stock
A - Award 31,500 31,500
2021-08-23 2021-08-23 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy)
M - Exercise -9,700 300,000 -3.13
2021-08-23 2021-08-23 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale X -9,700 0 -100.00 30.12 -292,190
2021-08-23 2021-08-23 4 AMTI Applied Molecular Transport Inc.
Common Stock
M - Exercise 9,700 9,700 4.61 44,717 44,717
2021-08-23 2021-08-19 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy)
M - Exercise -300 309,700 -0.10
2021-08-23 2021-08-19 4 AMTI Applied Molecular Transport Inc.
Common Stock
S - Sale X -300 0 -100.00 30.01 -9,003
2021-08-23 2021-08-19 4 AMTI Applied Molecular Transport Inc.
Common Stock
M - Exercise 300 300 4.61 1,383 1,383
2021-03-03 2021-03-01 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy)
A - Award 63,000 63,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)